ReviewDigestive diseases and sciences2017
Filling the Void: A Review of Intragastric Balloons for Obesity.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Randomized Prospective Clinical Study of Spatz3® Adjustable Intragastric Balloon Treatment with a Control Group: a Large-Scale Brazilian Experiment.Obesity surgery · 2021Trial
- Advances and future directions in endoscopic bariatric therapies.World journal of gastrointestinal endoscopy · 2025Review
- Endoscopic bariatrics: Current status and emerging technologies.World journal of gastrointestinal endoscopy · 2025Review
- Soft multistable magnetic-responsive metamaterials.Science advances · 2025Article
- Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy.Healthcare (Basel, Switzerland) · 2025Review
- Patient Complications and Device Issues Associated With FDA-Approved Intragastric Balloons Available in the USA: A Maude Database Study.Obesity surgery · 2024Article
- Emergent Management of Gastric Outlet Obstruction Post-Intragastric Balloon: A Case Report Highlighting the Importance of Preoperative Assessments and Postoperative Monitoring in Obesity Management.The American journal of case reports · 2024Article
- Efficacy and safety of intragastric balloon for obesity in Korea.Clinical endoscopy · 2023Article
- Endobariatrics: a Still Underutilized Weight Loss Tool.Current treatment options in gastroenterology · 2023Review
- Six intragastric balloons: Which to choose?World journal of gastrointestinal endoscopy · 2021Review
- Real-World Experience of Intragastric Balloons for Obesity: Insights from the FDA Manufacturer and User Facility Device Experience (MAUDE) Database.Obesity surgery · 2021Article
- Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses.Journal of clinical and translational hepatology · 2021Article
- [Intragastric balloon for weight reduction: rationale, benefits, risks and indications].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- New Era: Endoscopic treatment options in obesity-a paradigm shift.World journal of gastroenterology · 2019Review
- Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months.Obesity surgery · 2019Observational
- Life-threatening visceral complications after intragastric balloon insertion: Is the device, the patient or the doctor to blame?Endoscopy international open · 2019Review
- Intragastric Balloons for Overweight Populations-1 Year Post Removal.Obesity surgery · 2018Article
- Mechanical intestinal obstruction caused by displacement of a stomach balloon - case report.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2018Article
- Gastric outlet obstruction: a rare complication in patients with intragastric balloon treatment for obesity.BMJ case reports · 2018Article
- An Autopsy Case of Misdiagnosed Wernicke's Syndrome after Intragastric Balloon Therapy.Case reports in gastrointestinal medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic bariatric therapies are predicted to become much more widely used in North America for obese patients who are not candidates for bariatric surgery. Of all the endoscopic bariatric therapies, intragastric balloons (IGBs) have the greatest amount of clinical experience and published data supporting their use. Three IGBs are FDA approved and are now commercially available in the USA (Orbera, ReShape Duo, and Obalon) with others likely soon to follow. They are generally indicated for patients whose BMI ranges from 30 to 40 mg/kg
Indexed as
Identifiers
28421456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.